• Login
    Search 
    •   NWU-IR Home
    • Research Output
    • Search
    •   NWU-IR Home
    • Research Output
    • Search
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Search

    Show Advanced FiltersHide Advanced Filters

    Filters

    Use filters to refine the search results.

    Now showing items 1-10 of 64

    • Sort Options:
    • Relevance
    • Title Asc
    • Title Desc
    • Issue Date Asc
    • Issue Date Desc
    • Results Per Page:
    • 5
    • 10
    • 20
    • 40
    • 60
    • 80
    • 100
    Thumbnail

    Inhibition of monoamine oxidase by phthalide analogues 

    Strydom, Belinda; Bergh, Jacobus J.; Petzer, Jacobus P. (Elsevier, 2013)
    Based on recent reports that the small molecules, isatin and phthalimide, are suitable scaffolds for the design of high potency monoamine oxidase (MAO) inhibitors, the present study examines the MAO inhibitory properties ...
    Thumbnail

    The design and evaluation of an l-dopa-lazabemide prodrug for the treatment of Parkinson’s disease 

    Hoon, Monique; Petzer, Jacobus P.; Viljoen, Francois; Petzer, Anél (MDPI, 2017)
    l-Dopa, the metabolic precursor of dopamine, is the treatment of choice for the symptomatic relief of the advanced stages of Parkinson’s disease. The oral bioavailability of l-dopa, however, is only about 10% to 30%, and ...
    Thumbnail

    The monoamine oxidase inhibition properties of C6- and N1-substituted 3-methyl-3,4-dihydroquinazolin-2(1H)-one derivatives 

    Marais, Lereze; Petzer, Anél; Petzer, Jacobus P.; Legoabe, Lesetja J. (Springer, 2020)
    Quinazolinone compounds are of interest in medicinal chemistry since they display a wide range of biological properties. In the present study, a series of C6- and N1-substituted 3-methyl-3,4-dihydroquinazolin-2(1H)-one ...
    Thumbnail

    Exploring 4-substituted-2-thiazolylhydrazones from 2-, 3-, and 4-acetylpyridine as selective and reversible hMAO-B inhibitors 

    Chimenti, Paola; Petzer, Anél; Petzer, Jacobus P.; Carradori, Simone; D’Ascenzio, Melissa (Elsevier, 2013)
    A series of 4-substituted-2-thiazolylhydrazone derivatives have been synthesized and tested in vitro for their human monoamine oxidase (hMAO) A and B inhibitory activity. Our findings confirmed that the substitution at ...
    Thumbnail

    The interactions of caffeine with monoamine oxidase 

    Petzer, Anél; Pienaar, Anke; Petzer, Jacobus P. (Elsevier, 2013)
    Aims: Caffeine has been used as a scaffold for the design of inhibitors of monoamine oxidase (MAO) A and B. Substitution at the C8 position with a variety of moieties yields structures with high MAO inhibition ...
    Thumbnail

    Azure B and a synthetic structural analogue of methylene blue, ethylthioninium chloride, present with antidepressant-like properties 

    Delport, Anzelle; Harvey, Brian H.; Petzer, Anél; Petzer, Jacobus P. (Elsevier, 2014)
    Aims: The phenothiazinium compound, methylene blue (MB), possesses diverse pharmacological actions and is attracting attention for the treatment of bipolar disorder and Alzheimer's disease. MB acts on both monoamine oxidase ...
    Thumbnail

    The monoamine oxidase inhibition properties of selected structural analogues of methylene blue 

    Delport, Anzelle; Harvey, Brian H.; Petzer, Anél; Petzer, Jacobus P. (Elsevier, 2017)
    The thionine dye, methylene blue (MB), is a potent inhibitor of monoamine oxidase (MAO) A, a property that may, at least in part, mediate its antidepressant effects in humans and animals. The central inhibition of MAO-A ...
    Thumbnail

    Inhibition of monoamine oxidase by benzoxathiolone analogues 

    Mostert, Samantha; Petzer, Anél; Petzer, Jacobus P. (Elsevier, 2016)
    Inhibitors of the monoamine oxidase (MAO) enzymes are considered useful therapeutic agents, and are used in the clinic for the treatment of depressive illness and Parkinson’s disease. In addition, MAO inhibitors are also ...
    Thumbnail

    Caffeine as a lead compound for the design of therapeutic agents for the treatment of Parkinson’s disease 

    Petzer, Jacobus P.; Petzer, Anél (Bentham Science, 2015)
    The current pharmacological therapies for the treatment of Parkinson’s disease are mostly inadequate and recent, improved therapeutic agents are required. Two important molecular targets for the design of anti-parkinsonian ...
    Thumbnail

    Evaluation of natural and synthetic 1,4-naphthoquinones as inhibitors of monoamine oxidase 

    Mostert, Samantha; Petzer, Anél; Petzer, Jacobus P. (Wiley, 2016)
    Previous reports have documented that 1,4-naphtho- quinones act as inhibitors of the monoamine oxidase (MAO) enzymes. In particular, fractionation of the extracts of cured tobacco leafs has led to the charac- terization ...
    • 1
    • 2
    • 3
    • 4
    • . . .
    • 7

    Copyright © North-West University
    Contact Us | Send Feedback
    Theme by 
    Atmire NV
     

     

    Browse

    All of NWU-IR Communities & CollectionsBy Issue DateAuthorsTitlesSubjectsAdvisorThis CommunityBy Issue DateAuthorsTitlesSubjectsAdvisor

    My Account

    LoginRegister

    Discover

    AuthorPetzer, Jacobus P. (60)Petzer, Anél (51)Legoabe, Lesetja J. (13)Bergh, Jacobus J. (12)Carradori, Simone (5)Engelbrecht, Idalet (5)Harvey, Brian H. (5)Mostert, Samantha (5)Kabanova, Mariya V. (4)Malan, Sarel F. (4)... View MoreSubject
    Monoamine oxidase (64)
    Inhibition (34)MAO (21)Reversible inhibition (18)Reversible (12)Caffeine (10)Parkinson’s disease (9)Structure-activity relationship (9)Molecular docking (8)Competitive (7)... View MoreDate Issued2019 (11)2012 (9)2015 (7)2016 (7)2017 (7)2018 (6)2013 (5)2010 (4)2011 (4)2014 (2)Has File(s)No (58)Yes (6)

    Copyright © North-West University
    Contact Us | Send Feedback
    Theme by 
    Atmire NV